Agios Pharmaceuticals: Worthy Of Accumulation

Bret JensenInvesting Group LeaderFollow5ShareSavePlay(6min)CommentsSummaryAgios Pharmaceuticals remains a commercial-stage biotech focused on rare hemolytic anemias, with two indications now approved for its main asset.AGIO's recent FDA approval for mitapivat in thalassemia expands its addressable market, supporting the investment thesis.The company maintains a fortress balance sheet with $1.2 billion in cash, no long-term debt, and a recent $300 million annual cash burn.Analyst sentiment has turned somewhat positive post-Q4 results, reinforcing an accumulation case for risk-tolerant investors.An updated analysis around Agio Pharmaceuticals follows in the paragraphs below.Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » vdvornyk/iStock via Getty Images When I last looked at Agios Pharmaceuticals (AGIO) in mid-June of last year, I concluded that article noting that Agios had a fortress balance sheet. The stock merited a 'Speculative Buy' rating for risk-tolerant investors. The shares movedThis article was written byBret Jensen56.97K FollowersFollowBret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.Analyst’s Disclosure: I/we have a beneficial long position in the shares of AGIO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.